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Abstract
Background: Clinical trials have indicated that preclinical results obtained with human tumor xenografts in mouse
models may overstate the potential of adenovirus (Ad)-mediated oncolytic therapies. We have previously demonstrated
that the replication of human Ads depends on cyclin E dysregulation or overexpression in cancer cells. ED-1 cell derived
from mouse lung adenocarcinomas triggered by transgenic overexpression of human cyclin E may be applied to
investigate the antitumor efficacy of oncolytic Ads.
Methods: Ad-cycE was used to target cyclin E overexpression in ED-1 cells and repress tumor growth in a syngeneic
mouse model for investigation of oncolytic virotherapies.
Results: Murine ED-1 cells were permissive for human Ad replication and Ad-cycE repressed ED-1 tumor growth in
immunocompetent FVB mice. ED-1 cells destroyed by oncolytic Ads in tumors were encircled in capsule-like structures,
while cells outside the capsules were not infected and survived the treatment.
Conclusion: Ad-cycE can target cyclin E overexpression in cancer cells and repress tumor growth in syngeneic mouse
models. The capsule structures formed after Ad intratumoral injection may prevent viral particles from spreading to the
entire tumor.
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Background
Virotherapy with E1b55K-deleted adenoviruses (Ads),
which preferentially replicate in cancer cells causing
oncolysis and amplified efficacy, has been considered as
an emerging drug platform [1]. Although E1b55K-de-
leted ONYX-015 (dl1520) has been applied in clinical
trials and H101 (structurally similar to ONYX-015) has
been commercially approved for cancer treatment [2, 3],
the antitumor effects of oncolytic Ads have been some-
what disappointing in clinical applications [4, 5].
Clinical studies have indicated the importance of de-
veloping better preclinical tumor models [1]. Current
animal models used to evaluate the efficacy of oncolytic
Ads rely on human tumor xenografts in immunodefi-
cient mouse models. Nevertheless, such kind of human
tumor xenograft models are less clinically relevant. The
lack of functional immune systems in immunodeficient
models may hinder the accuracy of predicting the clin-
ical effects in human patients [6, 7]. Ads have complex
interactions with host immune response effectors [2, 8].
In the presence of the immune system, the oncolytic ef-
fects of the virus may be reduced due to the immune re-
sponses against viral particles. Conversely, the immune
system may rally round the tumor-killing effects by
recruiting natural killer cells, antibodies, or tumor-
specific cytotoxic T lymphocytes (CTLs) to enhance the
therapeutic outcome [9, 10]. Additionally, human Ads
tend to infect and replicate more efficiently in human
cancer cells than in normal murine tissues in the mouse
models. Thus, preclinical results obtained with human
tumor xenografts in mouse models may overstate the
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therapeutic potential. In fact, results of clinical trials
often fall short of hopes and expectations based on pre-
clinical animal studies. It has become clear that the de-
velopment of suitable immunocompetent murine cancer
models for studies of Ad-mediated oncolysis will benefit
the evaluation of virotherapies in more clinically relevant
settings.
It was originally proposed that the E1b55K-deleted
Ads could replicate only in p53-deficient tumor cells, as
the E1B55K-mediated degradation of p53 protein was
not required in those cancer cells [11, 12]. However, the
original hypothesis was challenged by several studies
showing that E1b55K-deleted Ads are able to replicate in
cells regardless of their p53 status [13–16]. Previously,
we have demonstrated that cyclin E dysregulation or
overexpression in cancer cells is an important molecular
basis of selective replication of E1b55K-deleted Ads in
human cancer cells [17, 18]. Wild-type Ad infection in-
duces cyclin E overexpression in normal and cancer
cells. E1b55K-deleted Ads fail to efficiently induce cyclin
E in normal cells, and thus viral replication is restricted;
however, E1b55K-deleted Ads can efficiently induce
cyclin E in cancer cells with dysregulated cyclin E
and successfully replicate in these cancer cells. We
have reported that Ad-induced cyclin E activates
CDK2 and targets the transcriptional repressor pRb
that may affect the cellular environment for viral pro-
ductive replication [19].
Cyclin E is a nuclear protein essential for the cell cycle
progression [20], DNA replication [21, 22], and centro-
some duplication [23, 24]. Numerous types of cancers
are highly associated with dysregulation of cyclin E [25].
Dysregulation of cyclin E occurs in more than 90 % of
lung, liver, and gastrointestinal cancers, and in more
than 80 % of glioma/blastoma, bone, and breast cancers
[26]. Constitutive overexpression of cyclin E induces
chromosome instability [27, 28], impairs normal cell
cycle progression, and triggers tumor development in
transgenic animal models [29–31]. Human cyclin E over-
expression in mouse lungs lead to the development of
premalignant and malignant lung lesions that resemble
the features found in lung cancer patients [31, 32]. A
murine ED-1 cell line was derived from lung cancers of
cyclin E transgenic mice [32, 33].
We have developed a novel E1b-deleted oncolytic Ad
vector, Ad-cycE, in which the E1a gene is under the con-
trol of the human cyclin E promoter [34]. With the dele-
tion of entire E1b region, Ad-cycE shares the replication
pattern similar to E1b55K-deleted dl1520 which relies
on the cyclin E overexpression in cancer cells. As the
cyclin E promoter is highly active in multiple types of
cancer cells and would be further stimulated after Ad in-
fection, Ad-cycE replication could be enhanced in cancer
cells. We showed that Ad-cycE elicits efficient antitumor
effects not only in cancer cells reported as permissive
for dl1520 replication but also in those reported as non-
permissive for dl1520. Ad-cycE significantly repressed
tumor growth in the immunodeficient nude mice bear-
ing human lung cancer xenografts. In this study, we
aimed to evaluate the impact of Ad-cycE in a more clin-
ical relevant model. We compared and characterized the
replication pattern of oncolytic Ads in human and mur-
ine lung cancer cells. Our results showed that the ED-1
murine cancer cells are permissive for human Ad repli-
cation, and that Ad-cycE significantly represses ED-1
tumor growth in immunocompetent mice. The availabil-
ity of this syngeneic model will allow the opportunity to
study the interaction between oncolytic viruses and the
immune system. Our model may provide a better pre-
clinical system to evaluate virotherapeutic efficacy,
safety, pharmacokinetics, and vector biodistribution.
Methods
Cell lines and culture conditions
HEK 293 (ATCC no. CRL-1573), human lung cancer
A549 (ATCC no. CCL-185), and mouse embryonic fibro-
blast NIH/3T3 (ATCC no. CRL-1658) cell lines were
purchased from the American Type Culture Collection
(Rockville, MD). The murine ED-1 cell line, a lung can-
cer cell line derived from transgenic mice with wild-type
human cyclin E under control of the human surfactant
C (SP-C) promoter [32, 33], was a gift from Dr. Ethan
Dmitrovsky's lab. HEK 293 and A549 cells were cultured
in minimal essential medium Alpha. ED-1 cells were cul-
tured in RPMI-1640 medium. All media were supple-
mented with 10 % fetal bovine serum (FBS) and
penicillin/streptomycin (100 U/ml). Cells were cultured
in a 5 % CO2 incubator at 37 °C.
Adenoviral vectors
Wild-type Ad type 5 (Adwt, ATCC no. VR-5) was used
as a replication-competent control. AdCMV/GFP, an Ad
vector with E1 deletion carrying a green fluorescent pro-
tein (GFP), was used as a replication-defective control.
Ad dl1520 is a E1b mutant that contains an 827-bp dele-
tion and a point mutation to generate a premature stop
codon in the E1B55K coding region [35]. Ad-cycE is a
novel E1b-deleted oncolytic vector carrying a human
cyclin E promoter driving an intact E1A expression cas-
sette [34]. All of the vectors created and used in this
study are based on the backbone of wild-type Ad type 5.
MTT assay
Cell proliferation was assessed at three days after re-
spective treatments by measuring the conversion of the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) to purple formazan, as previously de-
scribed [36]. The experiments were repeated at least
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three times. The results were expressed as the fold
change relative to the result at day 0. Doubling time was
analyzed from the cell growth curves on log phase with
the exponential regression analysis provided by http://
www.doubling-time.com/compute.php [37, 38].
Cytotoxicity assay
Cytotoxicity was assessed with crystal violet staining, as
previously described [39]. The OD values were quanti-
tated into the cell viability percentage by the equation:
cell viability % = (OD value of experimental group / OD
value of control group) × 100 %. The mock-control group
was calculated as 100 % of cell viability in the assay [40].
Southern blot analysis
After viral infection, cells were collected at different time
points. The viral DNA synthesis was determined with
Southern blot analyses, as described previously [17, 19].
The blot was pre-hybridized for 3 h at 63 °C. The
hybridization and stringency washes were performed at
60 °C and followed by the chemiluminescent detection,
according to the manufacturer’s protocol. Densitometric
value for the bands was quantified by Gel-pro Analyzer
4.0 software (Media Cybernetics, Bethesda, MD) [41]
and expressed as integrated optical density (I.O.D.).
Western blot analysis
Infected cells were harvested at indicated time points
and Western blot analyses were performed as described
previously [19, 42]. The primary antibodies used in this
study were rabbit anti-cyclin E (M-20), (Santa Cruz Bio-
technology, Santa Cruz, CA), mouse anti-Ad type 5 E1A
(BD Pharmingen, San Jose, CA), and rabbit anti-Ad type
5 antibody (Abcam, Cambridge, MA). The membranes
were then incubated with anti-mouse immunoglobulin
G (IgG) or anti-rabbit IgG peroxidase-linked species-
specific whole antibody (GE Healthcare, Piscataway, NJ).
Viral titration
Total infected cells and culture supernatants were col-
lected at the indicated time points and lysed to release
virus particles with three cycles of freezing and thawing.
The viral titers were determined by the infective unit
method, as described previously [43, 44]. Briefly, HEK
293 cells were seeded in 96-well plates at a density of
103 (cells/well) and then infected with 10-fold serially di-
luted viruses. Cytopathic effect (CPE) was recorded and
scored after incubation for 7 days.
Burst assay
Burst assays were used to determine the replication effi-
ciency of human Ads in infected cells [45–47]. Cells
were seeded in 6-well plates at a density of 2 x 105
(cells/well) for 4 h and infected with human Ads at 3.5
(for A549 cells) or 10 multiplicity of infection (MOI)
(for ED-1 cells). At 18 h post-infection (p.i.), cell super-
natants were removed, and the cell monolayers were
washed twice with phosphate buffered saline (PBS). At
18 h and 120 h p.i., cells and supernatants were col-
lected. The viral titers were determined by the infective
unit method. The burst ratio was expressed as the titer
of virus at 120 h p.i. (virus output) relative to the titer of
virus at 18 h p.i. (virus input). An increased ratio in virus
titer after 120 h indicates virus replication.
Syngeneic subcutaneous murine lung cancer study
Female FVB/NCr mice were obtained from National
Cancer Institute (Bethesda, MD). 5 x 106 ED-1 murine
lung cancer cells were subcutaneously injected into the
flanks of mice (age, 6 weeks). Once tumor volume
reached approximately 50 mm3, the mice were random-
ized and received 1.5 × 109 IFU of AdGFP or Ad-cycE in
50 μL of PBS every 2 days for a total of 4 treatments.
The tumors were measured every 3 days; the volume
was determined by externally measuring in 2 dimensions
with a caliper and calculated based on the following
equation: V = (L ×W2) / 2, where L is length and W is
width of the tumor. Animal experiments were performed
according to the institutional guidelines approved by the
University of Louisville Institutional Animal Care and
Use Committee.
Histological and immunohistochemical analyses
Tumors were harvested one week after the fourth treat-
ment, embedded in optimal cutting temperature compound
(O.C.T.) (Sakura Finetek, Torrance, CA), and stored
at −20 °C. The sections (8 μm) were subjected to ei-
ther hematoxylin-eosin (H&E) or immunohistochemi-
cal staining (IHC) as described previously [48]. For
IHC staining, the sections were incubated with goat-
anti-Ad polyclonal antibody (AB1056, Millipore, Bil-
lerica, MA) and diluted (1:800) for 1 h at room
temperature. The signals were amplified by a biotinyl-
ated anti-goat IgG diluted (1:200) in conjunction with
VECTASTAIN avidin-biotin complex method kit
(Vector Laboratories, Burlingame, CA). Visualization
was achieved using 3,3-diaminobenzidine tetrahydro-
chloride (ImmPACT DAB peroxidase substrate,
Vector Laboratories). Hematoxylin was used as a
counterstain. Images were acquired at X200 magnifi-
cation by using an Olympus BX53 microscope (Olympus,
Center Valley, PA).
Statistical analyses
Quantitation results were reported as means ± standard
deviation (S.D.). Statistical differences of the combin-
ation experiment were assessed with a Student's t-test.
Statistical significance of difference was set at p < 0.05.
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Results
Murine ED-1 cells show higher growth rate and lower
serum requirement than human A549 cells
The ED-1 cell line was derived from transgenic mice
with wild-type human cyclin E expression in lung can-
cers [32, 33]. The human A549 lung cancer cell line,
with constitutive cyclin E expression, is highly permis-
sive for oncolytic Ad replication [17]. The growth prop-
erties of ED-1 and A549 were compared to understand
the difference between the two cell lines. The final num-
ber of ED-1 cells increased 10 fold in 3 days, while A549
cells increased 5.6 fold (Fig. 1a). The doubling time gen-
erated from the ED-1 cell growth data in log phase was
18.60 h and A549 was 30.17 h, showing the ED-1 cell
growth rate was about 1.6-fold faster than that of A549
cells. Growth curves of A549 and ED-1 cells in the pres-
ence of serum concentrations, ranging from 0 to 10 %,
are shown in Fig. 1b. The number of A549 cells cultured
in medium with 0 % serum only increased slightly; how-
ever, ED-1 cells still increased close to 4 fold under the
same conditions. Thus, ED-1 cells grew significantly fas-
ter and exhibited less dependence on serum concentra-
tion than A549 cells.
Murine ED-1 cells require 3-fold higher titers of Ads to
achieve similar infection as human A549 cells
To evaluate the efficiency of human Ad infection of hu-
man and murine cancer cells under a similar growth rate
and a comparable density, A549 and ED-1 cells were
cultured in 1 % FBS and 0 % FBS, respectively. We first
evaluated the Ad infection by quantifying the number of
A549 and ED-1 cells expressing GFP after infection with
AdGFP (Fig. 2a). Infection with AdGFP at an MOI of 10
achieved maximum infection (>90 %) of A549 cells,
while an MOI of 20 infected only 80 % of ED-1 cells, in-
dicating poor infection of Ads in mouse cells. Consider-
ing that the activity of the cytomegalovirus (CMV)
promoter used to drive GFP expression in the vector
may differ in different cell lines, we also evaluated the
infection efficiency by quantitating the amount of Ad
DNA in cells. As AdGFP is a non-replicative virus, the
amounts of AdGFP DNA inside cells represent the total
viruses that entered into those cells. With the same MOI
of AdGFP infection, the Ad DNA amount in ED-1 cells
was lower than that in A549 cells (Fig. 2b). Yet, increas-
ing infection MOI of AdGFP led to a concomitant in-
crease of Ad DNA amount in both ED-1 and A549 cells,
suggesting that virus entry can be adjusted by altering
the infection MOI of Ads. To compare the concentra-
tion of Ad DNA in ED-1 and in A549 cells, we spe-
cifically quantitated the densities of a band of viral
DNA in ED-1 cells infected with 10 MOI of AdGFP
and in A549 cells infected with AdGFP at MOIs of
2.5, 5, and 10 (boxed in Fig. 2b). The algorithmic re-
sult revealed that an MOI of 10 of Ads for ED-1 cells
is required to achieve a similar infection of A549 cells
at an MOI of 3.5.
Human oncolytic Ads selectively replicate in murine ED-1
cancer cells
To understand the potential of murine ED-1 cancer cells
for the study of oncolytic virotherapy, we compared Ad
Fig. 1 Growth properties of human A549 compared with murine ED-1 cells. Cell proliferation and serum sensitivity of A549 and ED-1 cells were
determined by MTT assay at 0, 24, 48, and 72 h. A549 and ED-1 cells were seeded into 24-well plates at a density of 2.5 x 104 (cells/well) and
cultured in (a) 10 % fetal bovine serum (FBS) or (b) A549 and ED-1 cells cultured in 0, 0.5, 1, 2.5, 5, and 10 % FBS, respectively. The results were
expressed as the fold change relative to the result at 0 h. All values represent the means ± S.D. of triplicate samples
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replication in murine and human cancer cells. Murine
NIH/3T3 cells generated from NIH Swiss mouse embryo
fibroblasts [49] were applied here as a non-cancerous
control. Relatively higher levels of cyclin E expression
were detected in human A549 cancer cells, expression of
cyclin E was lower in the murine ED-1 cell, but not in
NIH/3T3 cells (Fig. 3a). Replication of wild-type Ad5
(Adwt), oncolytic dl1520 (ONYX-015), and Ad-cycE
were evaluated. AdGFP was used as a non-replicative
control. Ad dl1520 is an attenuated Ad with E1b
deletion, which has been studied in several clinical trials
[2, 35]. Ad-cycE is an E1b-deleted vector with its E1a
gene controlled by the human cyclin E promoter [34].
To achieve equal infections, we chose 3.5 MOI of Ad for
infection of human A549 cells and 10 MOI for murine
cells in our in vitro experiments. The photographs and
quantitated data of cell viability showed that mock-
infection and infection with non-replicative vector
AdGFP did not induce cytotoxicity (Fig. 3b). Adwt in-
duced cytotoxicity in all cell lines. However, the two
Fig. 2 Infection efficiency of human adenoviruses on A549 and ED-1 cells. (a) A549 cells were cultured with 1 % FBS, and ED-1 cells were cultured
with 0 % FBS at a density of 105 (cells/well) and infected with increasing MOI of AdGFP after seeding for 4 h. For each infection, three random
fields were taken by EVOS fluorescence microscope (AMG, Bothell, WA) at 72 h post-infection (p.i.). The numbers of GFP cells on each photo were
calculated by ImageJ (US National Institutes of Health, Bethesda, MD). The numbers of GFP-positive cells were divided by total cell numbers on
each photo to determine the infection efficiency. All values represent the means ± S.D. of triplicate samples. (b) A549 cells were cultured with 1 %
FBS, and ED-1 cells were cultured with 0 % FBS at a density of 106 (cells/well) in 60-mm dishes. Cells were infected with AdGFP at 0, 1.25, 2.5, 5,
10, and 20 MOI, respectively, and harvested at 24 h p.i. The DNA samples were digested with PstI, and then totally loaded into the agarose gel for
Southern blot analyses with Ad DNA fragments. The amounts of AdGFP entering cells were quantitated by Gel-pro Analyzer 4.0 software (Media
Cybernetics, Bethesda, MD) and presented as integrated optical density (I.O.D.) values. (Right, magnified view of boxed section.)
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oncolytic viruses, dl1520 and Ad-cycE, induced signifi-
cant cytotoxicity in both A549 and ED-1 lung cancer
cells but not in non-cancerous NIH/3T3 cells. This sug-
gests the selective cytotoxicity of oncolytic Ads for both
human and murine cancer cells.
To determine whether the cytotoxicity was caused by
complete virus replication in murine cells, burst assay
was used to determine the virus production. Yields of
Adwt, dl1520, and Ad-cycE increased over 100 fold in
ED-1 cancer cells. Adwt titers also increased in NIH/
3T3 cells, but dl1520 and Ad-cycE replication was
strongly repressed in NIH/3T3 cells (Fig. 3c). The results
indicate that Adwt can replicate in both cancer and
non-cancerous murine cells; however, dl1520 and
Ad-cycE can preferentially replicate in murine ED-1
cancer cells.
Fig. 3 Features of cancer selectivity of human oncolytic adenoviruses on murine cells. (a) Cells were seeded in 60-mm dishes at a density of 106
for 24 h and then collected. The cell lysates were immunoblotted for cyclin E protein and actin. Actin was used as a loading control. (b) Cells were
mock-infected or infected with AdGFP, Adwt, dl1520, or Ad-cycE at 3.5 MOI (for A549 cells) or 10 MOI (for ED-1 and NIH/3T3 cells). Cytopathic effect
(CPE) was observed at 72 h p.i. and photographed with an inverted microscope Olympus CKX41. The cell viability percentage was determined, and
the values represent the means ± S.D. of triplicate samples compared with the mock-infected group. (c) ED-1 or NIH/3T3 cells were infected with Adwt,
dl1520, and Ad-cycE at 10 MOI for 18 h or 120 h. The virus yields were determined by infection unit method and expressed as burst ratios, representing
virus yields at 120 h p.i. relative to virus yields at 18 h p.i. The values represent the means ± S.D. of triplicate samples
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To further characterize the properties of human Ad
replication in A549 and ED-1 cells, Ad DNA synthesis,
E1A expression, the production of viral capsid proteins,
and the virus yields were analyzed. Southern blot ana-
lyses showed that viral DNA levels increased from 24 to
48 h post infection (p.i.) in A549 and ED-1 cells infected
with Adwt, dl1520, and Ad-cycE (Fig. 4a). The level of
E1A expression was examined by Western blot analyses
at 24-h p.i. Ad E1A expression was only detected in the
groups infected with replication-competent Adwt,
dl1520, and Ad-cycE, but not in the groups mock-
infected or infected with AdGFP (Fig. 4b). Consistent
with the pattern of the viral early gene E1A expression,
capsid protein of viral late gene production at 72 h was
detected in both human and murine cancer cells in-
fected with Adwt, dl1520, and Ad-cycE (Fig. 4b). Virus
yields of human Ads in murine ED-1 cells and human
A549 cells increased over the time (Fig. 4c). The titers of
Adwt, dl1520, and Ad-cycE produced by A549 cell cul-
ture increased to ~109 (IFU/ml) at 72 h after infection,
while the virus titers produced by ED-1 were between
107 and 108 (IFU/ml) (Fig. 4c). Altogether, our data
Fig. 4 Characterization of human adenoviral replication on murine cells. (a) 3.5 MOI was used to infect A549 cells, and 10 MOI was used to infect
ED-1 cells to achieve the similar infection efficiency. Virus DNA synthesis was determined by Southern blot analyses. Multiple bands in the range
of 35–46 kDa were generated from the alternative splicing of E1A transcripts. (b) Cells were mock-infected or infected with AdGFP, Adwt, dl1520,
or Ad-cycE at 3.5 MOI (for A549 cells) or 10 MOI (for ED-1). Cells were collected at 24 h p.i., and the cell lysates were immunoblotted for E1A protein,
viral capsid protein, and actin. Actin was used as a loading control. (c) The virus yields were determined at 0, 24, 48, and 72 h p.i. with the infection unit
method. The values represent the means ± S.D. of triplicate samples
Cheng et al. BMC Cancer  (2015) 15:716 Page 7 of 12
demonstrate that Adwt and oncolytic dl1520 and Ad-
cycE can replicate in both human A549 and murine ED-
1 lung cancer cells.
Ad-cycE suppresses murine ED-1 tumor growth in
immunocompetent mice
The expression of the cyclin E gene in murine ED-1 cells
is under control of the human surfactant C promoter
(SP-C) promoter [32]. The SP-C promoter has been used
for lung epithelial cell-specific gene expression in trans-
genic models [50–53]. The SP-C promoter may be more
active in vivo than in vitro [54]. To evaluate the effect of
Ad-cycE in vivo, we subcutaneously injected murine ED-
1 lung cancer cells into immunocompetent FVB mice.
When tumors were approximately 50 mm3, the mice
were intratumorally injected for a total of 4 times with
total 6 × 109 IFU of AdGFP or Ad-cycE. The initial
reduction of tumor volumes in the Ad-cycE-treated
group was observed at day 9 after the first treatment.
Mice treated with Ad-cycE exhibited significant sup-
pression of tumor growth, with 60 % reduction in the
mean tumor volume as compared with mice treated
with control AdGFP at day 36 after the first treat-
ment (P = 0.0002, Fig. 5a).
To verify the virus replication in tumor tissue, tu-
mors from the mice were harvested at day 7 and ana-
lyzed with histological and immunohistochemical
analyses. H&E staining showed that some cancer cells
formed condensed structures in the tumor tissues
treated with Ad-cycE (Fig. 5b, panel ii, blue areas in-
dicated by arrows). In contrast, such structures did
not occur in the tumors treated with the control vec-
tor AdGFP (Fig. 5b, panel i). Immunohistochemical
studies with the antibody against the Ad hexon pro-
tein, the classic marker of virus particles produced in
cells [55], showed the expression of the viral hexon
protein in tumor tissues treated with Ad-cycE, but
not in the control group treated with AdGFP (Fig. 5b,
panels iii and iv), indicating de novo synthesis of Ad-
cycE viral late proteins. The strong hexon staining
regions (Fig. 5b, panel iv, brown areas indicated by
arrows) are consistent with the condensed structures
showed by H&E staining (Fig. 5b, panel ii, blue areas).
The magnified views further illustrated the possible
progression of the pathologic morphology change in
the tumor sections after Ad-cycE treatment (Fig. 5c).
The results showed that Ad-cycE-infected ED-1
tumor cells were encircled in capsule-like structures
and likely killed as a consequence of oncolytic Ad
replication indicated by the high level expression of
the viral hexon protein, forming vacuoles in the cap-
sules. However, cells outside of the capsules were not
infected by Ad-cycE and survived the treatment.
Discussion
Development of an immunocompetent murine model
for oncolytic Ad therapy is critical to accurately evaluate
and improve the efficacy and safety of this approach. In
this study, we have characterized human Ad replication
in murine ED-1 lung cancer cells and studied oncolytic
Ad therapies with ED-1 tumors developed in immuno-
competent mice. Our data revealed that E1b-deleted Ad
viruses replicated in the ED-1 cells and repressed ED-1
tumor growth in syngeneic immunocompetent mice.
Murine cells were generally considered not permissive
for human Ad replication [56]. We found in this study
that human Ads can infect ED-1 cells and selectively
replicate in and destroy the murine cancer cells. The
cross-species infection of human Ad in ED-1 cells can
be mediated via the homologous Ad receptor CAR on
murine cells [57], coreceptors such as integrins and hep-
aran sulfate glycosaminoglycans, or other unknown re-
ceptors. We observed that the virions of oncolytic Ads
were produced in murine cancer ED-1 cells, but not in
non-cancerous murine NIH/3T3 cells. Obviously, the
entire human Ad life cycle is completed in ED-1 lung
cancer cells, but restricted in NIH/3T3 cells. It has been
reported that human Ads normally undergo abortive
replication in murine cells [58, 59]. Virus yields of Ad2
and Ad5 in 3T3-Swiss and BALB/c 3T3 cells were re-
duced 3 to 5 logs compared to virus production in hu-
man cells [60, 61] and no infectious virus particles of
Ad12 were detected in murine 3T3 (embryo) and L
(connective tissue) cells [59, 62]. The block of human
Ad replication in murine cells may be related to the low
infectivity [63], unstable and reduced DNA synthesis
[59, 61, 64], abortive expression of late proteins, or the
defective assembly and maturation at an later stage of
viral replication cycle [59, 60, 62]. Previously, we ob-
served that human Ads induced cytotoxicity in Chinese
hamster ovary (CHO) cells; however, there was a lack of
late protein production that prevented infectious virion
production (Cheng and Zhou, unpublished data). While
the exact mechanism(s) supporting the complete multi-
plication process of human Ads in murine cancer ED-1
cells remains to be investigated, it is tempting to specu-
late that the human cyclin E overexpression in the cell
may play an important role. The human cyclin E gene in
ED-1 cells was validated by polymerase chain reaction
(PCR) [33] (Additional file 1: Figure S1A). We also per-
formed single-cell cloning and validated the level of cyclin
E protein expression in these subcloned ED-1 cells. The
cyclin E proteins were detected at 47 kDa and 37 kDa [32,
65] in parent ED-1 and all subclones (Additional file 1: Fig-
ure S1B). Any conclusions, though, cannot exclude the pos-
sibility that the cyclin E proteins detected in the cultured
ED-1 cells may be murine proteins, since the human cyclin
E gene is under the control of the SP-C promoter that may
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be restricted in cultured cells [54]. In our study, we ob-
served that the cyclin E protein produced in ED-1 cells was
much lower than that observed in A549 cells (Fig. 3a), that
may indicate the repression of the cyclin E expression
caused by the restricted SP-C promoter in ED-1 cells.
The transgenic cyclin E expression in ED-1 cells may
directly and indirectly affect the multiplication process
of oncolytic Ads. Under the normal condition, cyclin E
regulates cell cycle progression, DNA replication licens-
ing [21, 22, 66], centrosome duplication [23, 24], and
Fig. 5 Antitumor effects of human Ad-cycE on murine ED-1 tumor in FVB mice. Mice carrying established ED-1 tumors were treated with control
virus AdGFP or Ad-cycE on days 0, 2, 4, and 6. The total viral dose was 6 x 109 IFU/mouse. (a) The vertical arrow represents each treatment. Tumor
volume (V) was plotted against time and was determined by the equation V = (L × W2) / 2, in which L represents the length, and W represents the
width of the tumor. The values represent the mean tumor volumes ± S.D. * P < 0.05 compared with AdGFP control group (n = 5), Student’s t-test.
(b) H&E staining and immunohistochemical staining of tumor sections using anti-adenoviral hexon antibody. The representative photographs
were taken at original magnification X200. Arrows in panel ii point to formed, condensed structures in the tumor tissues. Arrows in panel iv point
to strong hexon staining. (c) The magnified views show the progression of pathologic morphology in the sections from mice treated with Ad-cycE
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E2F activation [67]. Cyclin E overexpression may cause
cell overgrowth and thus increase the accumulation of
mutations associated with tumorigenesis. Consequently
the alternations of the growth rate and genetic muta-
tions may create a suitable environment to loose cellular
restriction to viral propagation. Also, the excess cyclin E
may directly endorse virus replication. We previously
demonstrated that human Ad replication relies on cyclin
E induction in cells after viral infection [17]. Ad-induced
cyclin E turns on the pRb/E2F pathways by activating
CDK2 [19]. It is possible that human Ad replication in
murine ED-1 cells may be associated with cyclin E dys-
regulation or cell cycle alterations occurring in the car-
cinogenesis caused by the transgenic cyclin E expression.
We have investigated the antitumor efficacy of Ad-
cycE with murine tumors in immunocompetent FVB
mice. Interestingly, we identified that Ad-cycE-infected
cancer cells located in the specific areas where the clus-
ters of cells were encircled in capsule-like structures in
tumors (Fig. 5c). The capsule formation is likely associ-
ated with Ad oncolytic replication because tumors
treated with the control non-replicating AdGFP did not
exhibit such structures. We found that cells inside the
capsules died and formed vacuoles, but cells outside
were not infected and survived the treatment. Thus, the
capsule structures developed in tumors after Ad-cycE in-
fection may prevent viruses from spreading to the entire
tumor. In a previous clinical study, oncolytic Ads were
observed in clusters of 5–20 cells after intratumoral ad-
ministration, indicating that Ad spread in tumors is re-
stricted [68]. Viral spread within solid tumors is limited,
and usually is around the site of injection after intratu-
moral delivery [69, 70]. The movement of viruses
through tumors is likely impeded by the dense tumor
extracellular matrix [1]. Hyaluronan is a key component
of the tumor extracellular matrix. With an oncolytic Ad
expressing hyaluronidase to degrade this kind of import-
ant structural element of the ECM, Guedan et al. (2010)
showed that the virus distribution could be improved in
a human melanoma xenograft model [71]. Our results
indicate that the capsule structures may be formed as a
consequence of active tumor reactions to Ad replication
to prevent progeny Ad virions from spreading the infec-
tion to the rest of the cancer cells in tumors.
It is possible that the capsule structures may be also
associated with immune responses of FVB mice to Ad
replication. Hallden et al. (2003) reported that Ad5 sig-
nificantly induced intratumoral inflammatory cell infil-
tration, including macrophage and CD8(+) lymphocytes
[9]. The induction of non-specific or specific antitumor
immunity has been reported as one of the mechanisms
to mediate tumor cell lysis [72, 73]. The detailed mech-
anism by which the capsules formed in tumors requires
further study. The immune system of the ED-1 animal
model may have multiple effects on oncolytic virother-
apy. Further studies will clarify these immune-mediated
effects, such as the role of the immune cell infiltration
into the tumors on Ad spread in tumor. The ED-1 ani-
mal model as a preclinical system will also benefit the
development of future strategies to enhance viral pene-
tration and spread within solid tumors.
Conclusion
Our results showed that murine ED-1 cancer cells are
permissive for human Ad replication, and Ad-cycE sig-
nificantly represses ED-1 tumor growth in immunocom-
petent FVB mice. Such a model with the unique
background of cyclin E overexpression can provide a
suitable in vivo environment for researchers to study
oncolytic Ad replication in detail. Moreover, the capsule
structures formed in tumors may prevent viruses from
spreading to the entire tumor. The ED-1 model may
provide an opportunity to recapitulate clinical phenom-
ena and challenges for studies of virus spread in tumors
and the interactions between Ads and immune system.
An orthotopic tumor model based on this system can be
established to look at tumor growth and therapeutic effi-
cacy in the context of the lung microenvironment and
thus provide a valuable system to study oncolytic
virotherapy.
Additional file
Additional file 1: Figure S1. Characterization of cyclin E background in
murine ED-1 cells. (a) The genomic DNA was isolated from ED-1 cells,
and PCR was used to detect cyclin E with sense primer 5'-TTG GCT ATG
CTG GAG GAA GTA-3’ and antisense primer 5'-AGT GCT CTT CGG TGG
TGT CAT-3’. (b) The cell lysates from parent ED-1 and single-cell clones
were immunoblotted for cyclin E proteins. (TIFF 289 kb)
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